LPRP inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the LPRP protein, which is involved in various cellular processes, including protein-protein interactions and signal transduction pathways. Although the exact function of LPRP is not fully understood, it is believed to play a critical role in regulating specific pathways that are important for cellular communication and function. Inhibitors of LPRP are typically small molecules that interact with the protein by binding to its active site or other critical domains necessary for its activity. This binding prevents LPRP from carrying out its normal biological functions, which may involve the modulation of downstream signaling events or the stabilization of key protein complexes. The inhibition mechanism can vary, with some inhibitors competing directly with natural ligands or substrates, while others induce conformational changes that reduce the protein's activity.
The development of LPRP inhibitors involves extensive research into the protein's structure and the molecular interactions that are essential for its function. Techniques such as high-throughput screening are commonly used to identify lead compounds that exhibit potential inhibitory effects against LPRP. These compounds are then optimized through structure-activity relationship (SAR) studies, where their chemical structures are refined to enhance binding affinity, selectivity, and overall stability. The chemical makeup of LPRP inhibitors is diverse, with functional groups that enable strong interactions with the protein, including hydrogen bonds, hydrophobic interactions, and van der Waals forces. Advanced structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to visualize these interactions at an atomic level, providing detailed insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a crucial goal in the development of LPRP inhibitors, as it ensures that these compounds specifically target LPRP without affecting other proteins with similar structures or functions. This selectivity allows researchers to precisely modulate the activity of LPRP, enabling detailed studies of its role in cellular processes and its broader implications in cellular biology.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Inhibits AKT phosphorylation, which is critical for the PI3K/AKT signaling pathway that LPRP may utilize for its function in cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Blocks PI3K, thereby inhibiting the PI3K/AKT pathway, which reduces the activity of downstream proteins such as LPRP. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Irreversibly inhibits PI3K, leading to inhibition of the PI3K/AKT pathway, potentially reducing LPRP protein function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway, a potential pathway that LPRP may be involved in, resulting in functional inhibition. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase, potentially reducing the activity of downstream proteins such as LPRP that may operate downstream of EGFR signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Blocks RAF kinases, which may lead to reduced activity of the MAPK/ERK pathway, potentially diminishing the functional activity of LPRP. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Inhibits receptor tyrosine kinases, which could reduce the activity of signaling pathways that LPRP is involved in, thereby inhibiting its function. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2/neu which could lead to the inhibition of downstream signaling pathways involving LPRP. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits EGFR tyrosine kinase, potentially leading to a decrease in the activity of downstream proteins including LPRP. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially reducing the activity of signaling pathways involving LPRP. | ||||||